세계의 인간 오가노이드 시장 규모는 2025년부터 2032년까지 예측 기간 동안 12.85%의 연평균 복합 성장률(CAGR)로 확대될 전망이며, 2024년 12억 3,000만 달러에서 2032년에는 32억 3,000만 달러로 성장할 것으로 예측됩니다. 세계의 인간 오가노이드 시장은 암이나 신경 질환 등의 만성 질환의 유병률의 상승, 선진적인 창약 및 독성 모델에 대한 수요 증가에 의해 예측 기간 중에 성장할 것으로 예상됩니다.
인간 오가노이드는 생명공학과 생명과학의 혁신적인 돌파구로, 줄기세포의 진보, 혁신적인 약물 검출에 대한 수요 증가, 만성 질환의 유병률 증가로 인하여 인간 오가노이드 시장은 크게 성장할 준비가 되어 있습니다. 인간 줄기세포나 전구세포에서 유래하는 이러한 3D구조체는 기본적으로 인간의 장기의 구조나 기능을 재현한 것이며, 생물의학 연구를 위한 매우 현실적인 플랫폼 만들기 그리고 동물 모델을 대체하는 보다 정밀하고 윤리적인 선택을 제공합니다. 개별화 의료, 질병 모델링, 재생 요법은, 전세계의 제약 회사, 대학, 정부에의 투자에 의해서 급속히 추진, 개발되고 있습니다. 또, 암, 신경 변성 질환등의 복잡한 질환의 연구나 기존의 전임상 시험에 대한 오가노이드 기술의 도입도 시장을 지탱하고 있습니다. 인간 오가노이드 시장은 기술의 진보와 정밀 의료에 대한 관심의 고조에 힘입어 안정적인 성장이 전망되고 있습니다.
본 보고서에서는 세계의 인간 오가노이드 시장에 대해 조사했으며, 시장 개요와 함께 장기 유형별, 유래별, 용도별, 최종 사용자별, 지역별 동향 및 시장 진출기업 프로파일 등의 정보를 제공합니다.
Global human organoids market is projected to witness a CAGR of 12.85% during the forecast period 2025-2032, growing from USD 1.23 billion in 2024 to USD 3.23 billion in 2032. The global human organoids market is expected to thrive during the forecast period due to the increasing prevalence of chronic diseases such as cancer and neurological disorders and the rising demand for advanced drug discovery and toxicology models.
Human organoids are an innovative breakthrough in biotechnology and life sciences, with the market for human organoids prepared for significant growth due to the advances of stem cells, an increase in demand for innovative drug detection, and the growing prevalence of chronic diseases. These 3D structures, derived from the human stem or progenitor cells, are essentially replicas of human organs in terms of architecture and functionality, creating a highly realistic platform for biomedical research and offering more precise and ethical alternatives to animal models. Individualized medicine, illness modeling, and regenerative therapy are promoted and developed rapidly by investing in pharmaceutical companies, universities, and governments worldwide. The market is also supported by the introduction of organoid technology to study complex diseases such as cancer, neurodegenerative disorders, and conventional preclinical examinations. The human organoid market is expected to grow steadily, supported by technological advancements and growing interest in precision medicine. For instance, in November 2024, Axonis Therapeutics, Inc. used the International Space Station (ISS) National Lab to grow 3D brain organoids in microgravity, enabling successful testing of a reprogrammed viral vector for neurological gene therapy. This breakthrough advanced their therapeutic development and secured USD 115 million in funding for further research.
Increasing Prevalence of Chronic Diseases Boosts Market Growth
Increased incidences of chronic diseases represent a major growth driver in the human organoids market since such innovative 3D models provide unprecedented opportunities for understanding the complex mechanisms of diseases and developing targeted therapies. Cancer, diabetes, neurodegenerative diseases, and cardiovascular diseases are all gaining ground worldwide, creating a huge need for advanced research tools that can accurately recapitulate the functions of human organs. Human organoids represent a unique opportunity to model chronic disease progression in a controlled, human-friendly environment and test drug efficacy, thus identifying novel therapeutic targets. This is especially driven by the failure of traditional 2D cell culture and animal models to predict clinical outcomes. For instance, in June 2024, DefiniGEN Ltd. and Atelerix Ltd. successfully shipped stable in vitro liver models to a top United States pharma client. The models, combining induced pluripotent stem cells (iPSCs) derived hepatocytes and hydrogel preservation, enable efficient drug testing without the need for animal models, improving drug development and research processes.
Rising Demand for Advanced Models in Drug Discovery and Toxicology Drives Market Growth
Increasing demand for advanced drug discovery and toxicology models is a key growth driver for the global human organoids market because 3D models offer significant advantages over traditional 2D cell cultures and animal testing. Human organoids provide a more physiologically relevant platform for assessing drug efficacy, toxicity, and safety profiles, allowing pharmaceutical companies and research institutions to predict human responses better. Organoids made of cells that closely mimic the structure and complexity of human organs enable more accurate specification of potential drug candidates and long-term effects, thus increasing overall success in clinical trials. This propels market growth further, supported by advances in stem cell technology, investments in biotechnology, and the growing understanding of the limitations of traditional preclinical models.
For instance, in June 2023, Inventia Life Science Pty Ltd, a leader in advanced cell models, entered into a distribution agreement with Biotron Healthcare Pvt Ltd, granting Biotron sales rights for Inventia's RASTRUM platform in India. The RASTRUM platform, which enables the rapid creation of complex 3D cell cultures for disease modeling, drug discovery, and biomedical research, is designed for high-throughput applications. This partnership aims to enhance research capabilities in India, particularly in the pharmaceutical and academic sectors, by providing a simplified, automated solution to 3D bioprinting challenges.
Regenerative Medicine Segment to Dominate the Human Organoids Market
The regenerative medicine segment is projected to lead the global market for human organoids, led by the rising demand for new solutions in tissue repair and organ regeneration. Organoids are significant in advancing the prospects of regenerative therapies, especially for chronic diseases and organ failure, as they can replicate human organ functionality and structure. As the number of patients demanding personalized treatments surges, organoids create an important tool for simulating organ regeneration and forming patient-specific therapeutic strategies. Stem cell research and advancements in tissue engineering are also expanding the application of organoids in regenerative medicine through testing regenerative therapies and drug candidates much more effectively. The rising interest in reducing organ transplant dependency, along with the increasing capabilities of organoids to support tissue regeneration and repair, makes the regenerative medicine segment a promising growth driver in the market. For instance, in July 2024, Bioserve Biotechnologies (India) Private Ltd. launched advanced stem cell products from REPROCELL in India to advance scientific research, drug development, and regenerative medicine. The stem cell market, a rapidly growing sector, supports various industries involved in the research, manufacturing, and distribution of stem cell therapy products, driving innovation in therapeutic discovery.
North America Dominates the Human Organoids Market
North America is anticipated to be the dominating region in the human organoids market. Characterized by a strong research and development infrastructure, high governmental and private investments, and leading technological innovation. This region's key benefits are the presence of several giant pharmaceutical companies and academic centers engaged in the forefront of developing technologies for drug discovery, disease modeling, and personalized medicines. The presence of a favorable regulatory framework, as well as adequate funding for the field of regenerative medicine and stem cell research, boosts the adoption of human organoids in North America. Additionally, the growing demand for advanced, human-relevant models for preclinical drug testing, coupled with an increasing incidence of chronic diseases, propels the market growth. The FDA Modernization Act 2.0, signed in December 2022, permits the use of alternatives to animal testing, such as cell-based assays and computer models, for drug development. This shift aims to reduce costs, ethical concerns, and delays caused by animal model shortages, accelerating the drug approval process and fostering innovative testing methods.
Future Market Scenario (2025-2032F)
Developments in Stem Cell Technology: Technological progress in the sphere of stem cell research will gradually push the organoids ahead into more complex and better-fitting models for particular requirements.
Rise in Personalized Medication: The increasing tendency toward customized therapy, especially in cancer therapy and neurodegenerative conditions, increases the adoption of organoids in precision medicines.
Technological Innovation: Advances in 3D bioprinting, bioreactors, and scalable culture systems will enhance the functionality of organoids and make them more applicable in commercial settings.
Regulatory Support: Growing regulatory acceptance of organoid-based models for drug testing and disease research will support growth and adoption in the market.
Emerging Markets Growth: The increasing biotechnology investments and healthcare needs in regions such as Asia-Pacific and North America will lead to the rapid growth of the market in these regions.
Ethical Factors: The pressure for minimal animal testing combined with the ethical superiority of human-relevant models makes for the increased use of organoids in research and development.
Key Players Landscape and Outlook
The global human organoids market is segmented by organ type, including culture systems and bioreactors, and services, such as organoid-based research and drug testing. The fragmented services market contrasts with the type of market, dominated by key manufacturers. Recent developments include innovative launches, research center setups, and strategic mergers, driving growth in personalized medicine and regenerative therapies.
For instance, in May 2024, Crown Bioscience, Inc., signed a five-year collaboration agreement with the Shanghai Model Organisms Center (SMOC) to expand their immuno-oncology platforms and services globally. The agreement includes the supply of genetically engineered mouse models, cell line development, and custom model creation, offering uniform pricing, IP protection, and licensing rights across Crown's worldwide facilities.
For instance, in June 2023, AMSBIO Biotechnology (Europe) Limited launched MatriMix, a novel 3D culture substrate designed for advanced applications such as organoid formation and Induced Pluripotent Stem Cells (IPSCs) culture. This hydrogel contains fully defined components, including medical-grade collagens, laminin-511 E8 fragments, and hyaluronic acid, ensuring high lot-to-lot consistency and reproducibility. MatriMix addresses the limitations of current 3D substrates, providing superior performance in in-vivo animal PDX models and supporting cutting-edge biomedical research.
All segments will be provided for all regions and countries covered
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.